Heart Failure Clinical Trial
Official title:
Prediction of Cardiotoxicity Using Serum N-terminal Pro-B-type Natriuretic Peptide in Breast Cancer Patients Receiving Adjuvant Trastuzumab
Trastuzumab (Herceptin®) increases the chances of cure in patients with Her-2 overexpressing
early breast cancer. Unfortunately, both the chemotherapy drugs used in this setting
(anthracyclines) and trastuzumab are known to cause cardiac dysfunction in a proportion of
patients. Patients who develop heart problems when taking trastuzumab might have to stop
this treatment, which could jeopardise their chances of cure. N-terminal pro-B-type
natriuretic peptide (NT pro-BNP) is a cardiac biomarker that is measured in the blood, the
levels of which have been shown to indicate the presence of heart failure. Some early
research has suggested that there may be a correlation between elevated NT pro-BNP and heart
damage due to cancer chemotherapy and also trastuzumab. Troponin is another substance
measured in the blood that can indicate heart damage. Finally, certain variations in an
individual's genetic makeup (called polymorphisms) could put them at increased risk of heart
damage from trastuzumab. Here we are studying whether any of these factors (NT pro-BNP
levels, troponin levels, or certain genetic polymorphisms) can accurately predict who is at
highest risk of trastuzumab-related cardiotoxicity.
The principal aim of this study is to evaluate the utility of NT pro-BNP as a predictive
biomarker for the development of trastuzumab related cardiotoxicity (TRC). The investigators
will also examine if single nucleotide polymorphisms in the HER2 gene or Fc-gamma-receptor
genes predict for TRC.
n/a
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
| Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
| Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
| Active, not recruiting |
NCT05896904 -
Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction
|
N/A | |
| Completed |
NCT05077293 -
Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
|
||
| Recruiting |
NCT05631275 -
The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
|
||
| Enrolling by invitation |
NCT05564572 -
Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology
|
N/A | |
| Enrolling by invitation |
NCT05009706 -
Self-care in Older Frail Persons With Heart Failure Intervention
|
N/A | |
| Recruiting |
NCT04177199 -
What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
|
||
| Terminated |
NCT03615469 -
Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY)
|
N/A | |
| Recruiting |
NCT06340048 -
Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05679713 -
Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
|
||
| Completed |
NCT04254328 -
The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure
|
N/A | |
| Completed |
NCT03549169 -
Decision Making for the Management the Symptoms in Adults of Heart Failure
|
N/A | |
| Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
| Enrolling by invitation |
NCT05538611 -
Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
|
||
| Recruiting |
NCT04262830 -
Cancer Therapy Effects on the Heart
|
||
| Completed |
NCT06026683 -
Conduction System Stimulation to Avoid Left Ventricle Dysfunction
|
N/A | |
| Withdrawn |
NCT03091998 -
Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support
|
Phase 1 | |
| Recruiting |
NCT05564689 -
Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
|